Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.78%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B0.00%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA-0.02%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%HD+0.05%3988.HK-1.13%1816.HK+3.45%BAC+0.05%GE-0.03%0857.HK-0.49%ORCL-0.01%UNH+0.01%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.02%ORp-0.36%TM0.00%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.01%ETHUSD+71.01%USDTUSD+0.11%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.30%ZECUSDT+1.24%XMRUSDT+0.64%DOGEUSD+69.80%LINKUSD+2.34%XLMUSD-0.78%BCHUSDT-0.65%LTCUSD+68.40%UNIUSD-1.19%TONUSD+79.92%SUIUSD+1.11%HBARUSDT-0.24%TAOUSDT+2.24%AAVEUSD+0.86%ONDOUSDT+0.66%DOTUSDT+0.85%ICPUSDT+2.84%WLDUSDT+4.20%ARBUSDT+2.28%ATOMUSDT+0.27%INJUSDT+4.17%STXUSDT+2.59%PYTHUSDT+5.16%TIAUSDT+2.74%FETUSDT-1.64%SEIUSDT+0.59%JUPUSDT+3.25%GRTUSDT+0.51%OPUSDT+1.55%IOTAUSDT+1.65%POLUSDT+0.13%WIFUSDT+1.51%AXSUSDT-0.31%EOSUSDT+0.29%IMXUSDT+0.09%FARTCOINUSDT+0.78%GALAUSDT+2.69%DYDXUSDT-0.57%ORDIUSDT+2.26%NOTUSDT+1.19%RONINUSDT-0.96%AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.78%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B0.00%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA-0.02%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%HD+0.05%3988.HK-1.13%1816.HK+3.45%BAC+0.05%GE-0.03%0857.HK-0.49%ORCL-0.01%UNH+0.01%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.02%ORp-0.36%TM0.00%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.01%ETHUSD+71.01%USDTUSD+0.11%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.30%ZECUSDT+1.24%XMRUSDT+0.64%DOGEUSD+69.80%LINKUSD+2.34%XLMUSD-0.78%BCHUSDT-0.65%LTCUSD+68.40%UNIUSD-1.19%TONUSD+79.92%SUIUSD+1.11%HBARUSDT-0.24%TAOUSDT+2.24%AAVEUSD+0.86%ONDOUSDT+0.66%DOTUSDT+0.85%ICPUSDT+2.84%WLDUSDT+4.20%ARBUSDT+2.28%ATOMUSDT+0.27%INJUSDT+4.17%STXUSDT+2.59%PYTHUSDT+5.16%TIAUSDT+2.74%FETUSDT-1.64%SEIUSDT+0.59%JUPUSDT+3.25%GRTUSDT+0.51%OPUSDT+1.55%IOTAUSDT+1.65%POLUSDT+0.13%WIFUSDT+1.51%AXSUSDT-0.31%EOSUSDT+0.29%IMXUSDT+0.09%FARTCOINUSDT+0.78%GALAUSDT+2.69%DYDXUSDT-0.57%ORDIUSDT+2.26%NOTUSDT+1.19%RONINUSDT-0.96%

Gilead’s Livdelzi posts strong Phase 3 PBC data

NEWS

November 6, 2026 at 13:06 UTC

5 min read
Unbranded liver disease capsules on a clinical desk, illustrating strong Phase 3 data for GILD drug

Key Points

  • 01Phase 3 IDEAL trial shows 75.4% ALP normalization with Livdelzi at Week 52
  • 02Study targets PBC patients with ALP above normal but below 1.67× ULN
  • 03Treatment effect seen by month one and sustained through Week 52
  • 04Gilead (GILD) plans global regulatory talks that could widen Livdelzi’s use

Gilead’s IDEAL trial points to wider use for Livdelzi

Gilead Sciences (GILD) has unveiled detailed Phase III IDEAL study results showing that Livdelzi (seladelpar) significantly improved a key biochemical marker in adults with primary biliary cholangitis (PBC) whose alkaline phosphatase (ALP) levels are above normal but below 1.67 times the upper limit of normal. At Week 52, 75.4% of participants treated with Livdelzi achieved an ALP normalization composite endpoint, versus 16.1% of those receiving placebo. Gilead (GILD) plans to discuss these findings with global regulatory authorities, positioning the data as a potential basis for expanding Livdelzi’s use to a broader PBC population.

The ALP normalization endpoint in IDEAL was defined as ALP at or below 1.0 times the upper limit of normal and at least a 15% decrease from baseline. This composite response is aligned with recent treatment goals that emphasize ALP normalization as a key marker of disease activity and long-term outcomes in PBC. Livdelzi’s impact on achieving this endpoint underscores its role in addressing biochemical control in patients whose disease remains inadequately managed despite existing therapy or intolerance to standard treatment.

Trial design focuses on a previously under-studied group

IDEAL enrolled 96 adults aged 18 to 75 years with PBC whose ALP levels were above normal but below 1.67 times the upper limit of normal, despite at least 12 months of treatment with ursodeoxycholic acid (UDCA), or who were unable to tolerate UDCA. This group has generally been excluded from previous pivotal trials of second-line PBC therapies, leaving limited evidence to guide treatment decisions for these patients. By specifically targeting this population, IDEAL provides new data on Livdelzi’s effect in a segment of patients considered traditionally underserved in clinical research.

In the trial, participants receiving Livdelzi continued background UDCA if tolerated, reflecting real-world second-line treatment scenarios. The study’s primary objective was to compare Week 52 ALP normalization rates between Livdelzi and placebo in this defined ALP range. Exploratory endpoints included changes in other markers of cholestasis and liver injury.

Rapid and sustained biochemical responses

IDEAL demonstrated that Livdelzi’s effect on ALP occurred quickly and was maintained over time. After one month of treatment, 52.3% of Livdelzi-treated participants had already reached the ALP normalization composite endpoint, compared with 6.5% in the placebo arm. These improvements were sustained through Week 52, supporting a profile of both rapid onset and durable biochemical response in this PBC population.

Researchers reported that 75.4% of patients receiving Livdelzi achieved ALP normalization by Week 52, versus 16.1% on placebo, underscoring a substantial treatment difference. Clinicians involved in the study indicated that these findings can inform individualized treatment discussions by providing evidence of improved biochemical responses in patients whose ALP remains elevated but below 1.67 times the upper limit of normal. The results are being presented at The Liver Meeting 2026 in Denver and have been accepted for publication in the Journal of Hepatology.

Safety profile consistent with earlier Livdelzi studies

Safety findings from IDEAL were consistent with previously reported Livdelzi trials. No new safety concerns were identified, and there were no treatment-related serious adverse events. Serious adverse events occurred in 3.1% of participants receiving Livdelzi and 12.9% of those on placebo, with none considered related to the study drug. Livdelzi was described as safe and tolerable in the IDEAL population, reinforcing earlier experience with the therapy.

Livdelzi is an oral PPAR-delta agonist indicated in the United States for the treatment of PBC in combination with UDCA in adults who have had an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This indication was granted under the U.S. Food and Drug Administration’s accelerated approval pathway based on reduction of ALP, and improvement in survival or prevention of liver decompensation events has not been demonstrated. Ongoing and future studies, including IDEAL, are intended to further describe Livdelzi’s clinical benefit in PBC.

Regulatory path and implications for PBC care

Gilead is now engaging with global regulatory authorities to discuss the IDEAL findings in the context of Livdelzi’s existing PBC indication. The company has indicated that IDEAL, together with the broader Livdelzi clinical program, reinforces the importance of raising expectations for PBC care across a wide range of patients. If regulators accept these data, Livdelzi could potentially reach a larger population of PBC patients, including those whose ALP levels fall within the 1 to 1.67 times upper limit of normal range.

PBC is a chronic autoimmune disease of the bile ducts that affects approximately 130,000 people in the United States and occurs more commonly in women. ALP is a recognized marker of disease activity and long-term outcomes in PBC, and the IDEAL results are presented as expanding understanding of treatment effects in relation to evolving therapeutic goals. By demonstrating robust ALP normalization rates in an under-studied population, Livdelzi’s new data may influence future standards for biochemical control in second-line PBC management.

Key Takeaways

  • 01IDEAL is the first Livdelzi trial focused on PBC patients with ALP between 1 and 1.67 times the upper limit of normal, a group often excluded from prior pivotal studies.
  • 02Livdelzi produced rapid ALP normalization by one month and maintained this benefit through one year, suggesting durable biochemical control in the studied PBC population.
  • 03Consistent safety results, with fewer serious adverse events than placebo and none deemed drug-related, strengthen the case for broader regulatory consideration of Livdelzi.

Gilead’s Livdelzi posts strong Phase 3 PBC data | Trading Dashboard